Interações de Milnaciprana
Milnaciprana (Savella), IRSN, tem 193 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 95; moderadas: 94; leves: 3; casos em que uma bula relata não haver interação significativa: 1). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.
Interações segundo a bula
Interações graves (95)
Avoid concomitant use of milnacipran hydrochloride in patients with substantial alcohol use or chronic liver disease ( 5.6 ). (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (bula de Milnaciprana, Advertências e precauções)
In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (bula de Milnaciprana, Contraindicações)
• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Beladona + ópio, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Buprenorfina, Interações medicamentosas)
Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Buprenorfina + naloxona, Interações medicamentosas)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)
• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Butalbital + paracetamol + cafeína + codeína, Interações medicamentosas)
…medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ]. Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Butorfanol, Precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Codeína, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (bula de Dextroanfetamina, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Avoid co-administration of milnacipran hydrochloride and intravenous digoxin [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (bula de Edoxabana, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Combinar a erva-de-são-joão (hipérico) com antidepressivos e outros medicamentos serotoninérgicos aumenta o risco de síndrome serotoninérgica. (NCCIH, St. John's Wort)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (bula de Milnaciprana, Contraindicações)
• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Fentanila, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona, Interações medicamentosas)
Serotonergic drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + clorfeniramina, Interações medicamentosas)
Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + homatropina, Interações medicamentosas)
S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + ibuprofeno, Precauções)
Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + paracetamol, Precauções)
• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidromorfona, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (bula de Milnaciprana, Contraindicações)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Levorfanol, Precauções)
In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (bula de Milnaciprana, Contraindicações)
Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Lisdexanfetamina, Advertências e precauções)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Metadona, Advertências e precauções)
Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Metanfetamina, Advertências e precauções)
Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (bula de Metaxalona, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Morfina, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oliceridina, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (bula de Oxicodona, Interações medicamentosas)
Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oximorfona, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Paracetamol + codeína, Precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Pentazocina + naloxona, Precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Prometazina + codeína, Interações medicamentosas)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (bula de Milnaciprana, Contraindicações)
• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Remifentanila, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (bula de Milnaciprana, Contraindicações)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (bula de Milnaciprana, Contraindicações)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Ziprasidona, Advertências e precauções)
• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)
Interações moderadas (94)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (bula de Nalbufina, Interações medicamentosas)
The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (bula de Milnaciprana, Interações medicamentosas)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (bula de Milnaciprana, Interações medicamentosas)
Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)
Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Milnaciprana, Advertências e precauções)
Menções leves (3)
Clonidine: Because milnacipran hydrochloride inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine’s anti-hypertensive effect. (bula de Milnaciprana, Interações medicamentosas)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (bula de Milnaciprana, Interações medicamentosas)
Nenhuma interação significativa relatada (1)
Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples… (bula de Lumateperona, Interações medicamentosas)
Verifique Milnaciprana com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.
Abrir no verificadorNão é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.